Tilray Brands Surges 27.5% on Marijuana Reclassification Signals from Trump Administration

Tilray Brands (NASDAQ: TLRY) experienced a significant rally today, climbing 27.5% while the broader S&P 500 slipped 0.3% and the Nasdaq Composite edged up 0.2%. The surge reflects investor optimism following President Trump’s announcement that his administration is actively exploring a reclassification of cannabis to Schedule III controlled substances.

The Policy Catalyst: What Schedule III Reclassification Means

From the Oval Office, Trump indicated that reclassifying marijuana is under serious consideration, noting substantial public support for the move. This potential shift represents a watershed moment for the cannabis industry. Should the administration proceed, the change would dramatically ease the tax burden currently crushing cannabis operators and mark meaningful progress toward broader federal legalization.

Currently, cannabis remains a Schedule I substance alongside heroin and LSD, imposing severe restrictions on businesses. Downgrading it to Schedule III would represent a fundamental reimagining of federal cannabis policy and could unlock significant commercial opportunities for industry players like Tilray.

Why This Matters for Cannabis Companies

The reclassification wouldn’t constitute full legalization, but it would be transformative nonetheless. Cannabis firms would gain access to conventional banking services, reduced regulatory compliance costs, and the ability to deduct ordinary business expenses—advantages currently denied to Schedule I operators. These practical benefits would immediately improve profitability and operational efficiency.

Political momentum exists for this change across party lines, making implementation plausible despite previous administrations’ inaction on the reclassification question.

Evaluating Tilray’s Investment Case

Tilray’s financial performance remains underwhelming relative to investor expectations. The company has successfully reduced operating expenses and streamlined operations, yet profitability challenges persist. The stock remains speculative and carries elevated risk.

However, for investors with genuine conviction about legalization prospects and a multi-year investment timeline, Tilray warrants consideration. A successful reclassification or eventual full legalization would fundamentally reshape the business model, potentially unlocking substantial returns. The risk-reward equation tilts favorably only for those comfortable with cannabis sector volatility.

The path forward depends on whether Trump follows through on this policy exploration—but today’s market reaction suggests investors are pricing in meaningful probability of action.